We are revisiting this area to explore how the oligonucleotide field has actually developed and provide a critical review of where we are now.
Neil Henderson discusses his experiences with oligonucleotides, the technologies that he uses and his work as part of the Translational Biomarker and Bioanalysis group at Astrazeneca.
Challenges and future predictions for oligonucleotide analysis: an interview with Hans-Peter Vornlocher
In this interview Hans-Peter Vornlocher, managing Director of Research at LGC Axolabs (Kulmbach, Germany), reflects on his career in the oligonucleotide field discussing the benefits and challenges of using oligonucleotides, his future predictions and what emerging technologies could aid analysis in the future.
Beyond aptamers: selection of functional oligonucleotide, characterization, chemical synthesis and biotechnological application
In this review article the authors summarize the current development of functional oligonucleotides, called aptamers, focusing on the diagnostic and therapeutic applications.
This infographic presents key results from the oligonucleotide survey.
Bioanalysis of Diagnostic and Therapeutic Oligonucleotides: An Emphasis on LC-FL and LC-MS Based Assays
In this article, recent developments and considerations for liquid chromatographic (LC) methods of oligonucleotides are discussed, highlighting LC-Mass Spectrometry and LC-Fluorescence assays, and the benefits of systematic incorporation into a bioanalysis laboratory.
In this article Johannes Winkler discusses how the recent clinical successes prove that synthetic oligonucleotides are useful therapeutic agents and outlines some obstacles that need to be overcome for a more widespread and safe application.
In this interview, Min Meng discusses the changing landscape of oligonucleotides in bioanalysis, including how the industry has changed over the last decade as well as the advantages and disadvantages of different analytical methods.
LGC (Teddington, UK) have announced the combination of their Biosearch oligonucleotide reagent group with the newly acquired LINK technology, in the hope of enhancing oligonucleotide capabilities.
Mini webinar: Analytical approaches for quantitative determination of therapeutic oligonucleotides from biological samples
Introduction of the Axolabs PNA-HPLC Assay for selective and sensitive bioanalysis of all kinds therapeutically relevant oligonucleotide entities up to 100nt in length.